42nd Annual JP Morgan Healthcare Conference

We have a proven track record of building billion-dollar franchises Petcare innovation differentiates Zoetis Zoetis 2022 revenues: Dermatology $1.3B vs. <$1M in 2013 apoque) apoque) CYTOPOINT. oclacitinib chewable (oclacitinib chewable tablet) 1 Zoetis internal estimates Parasiticides $1.6B vs. $373M in 2013 Simparica Simparica TRIO revolution PLUS stronghold PLUS Next Big Opportunity Expected Zoetis peak annual revenue ¹: Osteoarthritis Pain (OA) $1B+ Librela Solensia Bedinvetmab Frunevetmab zoetis

View entire presentation